H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted

Pixabay/Public Domain

The updated protocol raises the people enrollment to astir 60 patients from the primitively intended 50, implying a absorption connected improving hazard mitigation and information comprehension alternatively than discontinuing the cause altogether.

H.C. Wainwright highlighted that the information incidents that triggered the clasp were uncommon, with 2 Grade 4/5 liver incidents, 1 of which was fatal, occurring successful astir 450 treated patients, accounting for little than 0.5% of the group.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is simply a biotech institution astatine the forefront of CRISPR-Cas9 gene-editing technology, processing cutting-edge treatments for some successful vivo and ex vivo applications. Its main initiative, NTLA-2001, aims to dainty transthyretin amyloidosis, an incurable disease.

While we admit the imaginable of NTLA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.